FSD Pharma Inc

Chart & Performance

D1W1MN

P/E

—

P/S

—

EPS

—

Div Yield, %

—

Shrs. gr., 5y

77.73%

Rev. gr., 5y

69.97%

Revenues

Net income

-26m

L+84.30%

CFO

-8m

L+21.88%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Profile

FSD Pharma Inc. functions as a biotechnology firm dedicated to the discovery and advancement of pharmaceutical products. Its main drug candidate, FSD201, is a palmitoylethanolamide currently undergoing development for addressing inflammatory conditions. Furthermore, the company is pursuing research and development into Lucid-Psych, a molecular compound targeting mental health challenges, and Lucid-MS, another molecular compound designed for neurodegenerative illnesses. FSD Pharma Inc. maintains its corporate headquarters in Toronto, Canada.

URL

https://www.fsdpharma.com/

IPO date

May 29, 2018

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑08
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT